MATR3 S85C

MATR3 (Matrin-3) is an RNA-binding protein that resides in the nucleus where it plays multiple essential roles in processing RNA, including regulating splicing (how genes are assembled into functional instructions) and transporting messenger RNA [1][3]. The protein is crucial for normal neuronal function and gene regulation, with recent evidence showing it helps control expression of immune-related genes in the context of ALS [4] and regulates important neuronal genes like UNC13A [1]. The S85C mutation, which replaces a serine amino acid with cysteine at position 85, is the most frequently observed disease-causing variant in MATR3 and causes both autosomal dominant ALS and distal myopathy [2][3]. The structural prediction for MATR3 S85C generated by AlphaFold2 shows an exceptionally low average confidence score of 55.2 pLDDT, indicating that most of the protein structure cannot be reliably predicted. Confidence scores below 70 pLDDT suggest regions that are either intrinsically disordered (lacking stable structure) or highly flexible, and MATR3 appears to contain extensive such regions. This low predicted confidence aligns with MATR3's known properties as an RNA-binding protein, since many proteins in this family contain intrinsically disordered regions that allow them to interact flexibly with RNA and other proteins. The S85 position falls within the N-terminal region of MATR3, but the low confidence prediction prevents detailed structural analysis of how the serine-to-cysteine substitution might alter local protein folding. Functional studies have revealed important insights into how the S85C mutation impacts MATR3 function. Research shows that this pathogenic variant reduces MATR3 solubility (making it more prone to clumping) but interestingly does not impair its ability to bind RNA [3]. The mutation appears to differentially affect MATR3's role in preventing aberrant splicing, a function where MATR3 normally suppresses inclusion of "cryptic exons" (usually hidden gene segments) into mature RNA transcripts [3]. This splicing dysfunction may contribute to disease pathology, particularly since MATR3 works in concert with other ALS-associated proteins like TDP-43, FUS, and hnRNPA1 to regulate critical genes involved in neuronal function [1]. Additionally, MATR3 activity is regulated by neuronal activity in a calcium-dependent manner, and the protein can be cleaved by calcium-activated enzymes, suggesting a complex relationship between neuronal excitability and MATR3 function that may be disrupted by disease mutations [5]. Clinical manifestations of S85C MATR3 mutations are heterogeneous, with patients presenting variable combinations of motor neuron disease and myopathy features [2]. The mutation causes autosomal dominant disease, meaning a single copy of the mutated gene is sufficient to cause illness. Case series have documented the variable expressivity of this mutation, with some individuals primarily showing distal muscle weakness while others develop more classic ALS features with motor neuron degeneration [2]. Interestingly, animal models have shown variable success in recapitulating disease features, with at least one MATR3 mutation knock-in mouse model (P154S) failing to develop ALS-like pathology [6], suggesting that disease mechanisms may be complex and potentially require additional factors or stressors beyond the mutation alone. The difficulty in predicting MATR3 structure with high confidence, combined with evidence that the protein contains functionally important disordered regions, underscores the challenge in understanding disease mechanisms through structure alone and highlights the importance of experimental studies examining protein solubility, RNA binding, splicing regulation, and cellular localization.